BIIB Earnings Prediction
The chart below shows how BIIB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BIIB sees a +3.61% change in stock price 10 days leading up to the earnings, and a +1.20% change 10 days following the report. On the earnings day itself, the stock moves by -2.51%. This data can give you a slight idea of what to expect for the next quarter's release.
BIIB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
2.45B
2.87%
-0.45%
Gross Margin
72.52%
2.31%
5.39%
Operating Margin
23.41%
9.09%
-0.97%
Net Margin
10.86%
4.12%
-31.09%
EPS
1.83
7.02%
-31.20%
No Data Available
BIIB Earnings Analysis
Biogen Inc Corporation (BIIB.O) Earnings Conference Call
Positive
Quarterly Revenue Growth: Total revenue for the fourth quarter was $2.5 billion, representing a 3% growth from the previous quarter, indicating a positive trend in overall financial performance.
Earnings Growth Surge: Fourth quarter non-GAAP diluted EPS was $3.44, which is 17% higher than the same quarter last year, showcasing strong earnings growth.
Rare Disease Revenue Growth: The rare disease franchise generated $535 million in revenue for the fourth quarter, reflecting a 13% increase at actual currency and a 15% increase at constant currency compared to the previous year.
Skyclaris Revenue Surge: Global Skyclaris revenue reached $102 million in the fourth quarter, marking an 83% increase year-over-year, driven by nearly double the number of patients on therapy.
Free Cash Flow Improvement: Free cash flow for the full year was $2.7 billion, an improvement of $1.4 billion from the previous year, demonstrating strong cash generation capabilities.
Negative
Revenue Decline Trend: Total revenue for the full year 2024 declined by 2% from 2023, indicating a downward trend in overall financial performance.
Multiple Sclerosis Revenue Decline: Multiple sclerosis product revenue declined by approximately 8% in Q4 2024 compared to Q4 2023, primarily due to increased competition and generic entries.
Contract Manufacturing Revenue Decline: The revenue from contract manufacturing decreased by $247 million, contributing to the overall revenue decline and highlighting challenges in this segment.
Revenue Decline Forecast: Full year 2025 revenue is expected to decline by a mid-single digit percentage, driven by anticipated further declines in the MS business due to potential biosimilar entries.
Increased Financial Burdens: Non-GAAP other expense was $72 million in Q4 2024, primarily driven by net interest expense, indicating increased financial burdens on the company.
BIIB FAQs
How does BIIB typically perform around its earnings report dates?
Is Biogen Inc (BIIB) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BIIB Earning Call Sentiment
Earnings call transcript: Biogen Q4 2024 EPS beats estimates, stock drops
BIIB.O
-0.43%Positive
The earnings call presents a mixed picture. While there is growth in EPS and certain product revenues, overall revenue is declining, and there are competitive pressures. The raised guidance and strong free cash flow are positives, but the market's concerns about competition and lack of clarity on some strategic aspects temper enthusiasm. The Q&A highlighted potential risks and management's evasive responses. Without a clear market cap, the prediction is neutral as the positives and negatives seem to balance out.
